17,261 trials
Asthma
Primary: Percentage Change From Baseline (for Each Treatment Cycle) in Exhaled Nitric Oxide (eNO) — 36.65; 45.31; 54.58 Percentage change in eNO
Liposarcoma · Leiomyosarcoma
Primary: Time to Progression- Independent Review — 3.7; 2.3 months — p=0.0302
Cocaine-Related Disorders
Primary: Weekly Cocaine Use — 1.1; 1.3 days
Non-Hodgkin's Lymphoma · Diffuse Large Cell Lymphoma · Mantle Cell Lymphoma
Primary: Event-free Survival (EFS) — 83 percentage of not experiencing EFS event
HIV Infections
Primary: Change in Percent CD8 HLA-DR+/CD38+ From Baseline to Week 12 — -2.0; -0.5; -3.1; -1.2 percent of CD8 expressing HLA-DR+/CD38+ — p=0.428
Malignant Melanoma
Primary: Positive Response Defined as Clinical Complete Response, Partial Response or Stable Disease (Persisting for at Least 4 Weeks) as Measure by Modified RECIST Criteria — 16…
Type 1 Diabetes Mellitus
Primary: Area Under the Insulin Concentration-time Curve for the First Hour (AUC0-60) — 12346.67; 8297.62; 11607.65; 4331.76 nanomole*minute per liter (nmol*min/L) — p=0.0011
Post-concussive Symptoms · Traumatic Brain Injury
Primary: Post-Intervation Post-concussion Symptom Scores Using RPQ - Intent to Treat — 3.5; 5.1; 4.2; 3.5 units on a scale
Follicular Lymphoma · Small Lymphocytic Lymphoma · Lymphoplasmacytic Lymphoma
Primary: Overall Response Rate — 57.6 percentage of participants — p=< 0.0001
Asthma
Primary: Weighted Mean Forced Expiratory Volume in 1 Second (FEV1) Measured Over 24 Hours at Day 14 of Each Treatment Period — 3.303; 3.332; 3.227 Liters
Influenza
Primary: Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strain. — 43; 121; 109; 57…
Bipolar Disorder
Primary: Mania Symptoms Using MACS — 18.6; 11.0 units on a scale — p=0.01
HIV Infections
Primary: Changes in GI Symptom Per Intervention Session — -0.24; -0.08; -0.09; -0.09 units on a scale
Dementia With Lewy Bodies (DLB)
Primary: Change From Baseline in Mini-mental State Examination (MMSE) Total — 20.9; 18.6; 0.3; 2 Score on a Scale
Gaucher Disease, Type 1 · Cerebroside Lipidosis Syndrome · Glucocerebrosidase Deficiency Disease
Primary: Percentage of Participants Demonstrating A Meaningful Clinical Response — 77 percentage of participants